EMEA-001964-PIP01-16-M01

Key facts

Active substance
Cannabidiol
Therapeutic area
Neurology
Decision number
P/0047/2020
PIP number
EMEA-001964-PIP01-16-M01
Pharmaceutical form(s)
Oral solution
Condition(s) / indication(s)
  • Treatment of seizures associated with Dravet Syndrome (DS)
  • Treatment of seizures associated with infantile spasms (IS)
  • Treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)
  • Treatment of seizures associated with Tuberous Sclerosis Complex (TSC)
Route(s) of administration
Oral use
Contact for public enquiries
GW Pharma (International) B.V.
E-mail: info@gwpharm.com
Tel: +44 1223266800
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating